Information Provided By: 
Fly News Breaks for December 5, 2017
COLL, DEPO
Dec 5, 2017 | 09:21 EDT
As previously reported, Mizuho analyst Irina Koffler upgraded Depomed (DEPO) to Buy from Neutral after the company agreed to license rights to commercialize the Nucynta franchise to Collegium (COLL). With the deal, Depomed exits the opioid space and significantly lowers its operating expenses, said Koffler, who raised her price target on Depomed shares to $9 from $6.
News For DEPO;COLL From the Last 2 Days
There are no results for your query DEPO;COLL
